| Edward Anthony Malcolm, DO | |
|
7700 S Broadway, Littleton, CO 80122-2602 | |
| (303) 730-8900 | |
| Not Available |
| Full Name | Edward Anthony Malcolm |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 11 Years |
| Location | 7700 S Broadway, Littleton, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629416862 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | DR.0055702 (Colorado) | Secondary |
| 207R00000X | Internal Medicine | 0055702 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Littleton Adventist Hospital, Centura Health | Littleton, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Portercare Adventist Health System | 0941110886 | 547 |
News Archive
Commonwealth Biotechnologies, Inc. ("CBI" or "Company")) (NASDAQ Capital Market:CBTE) today announced that on September 15, 2009, CBI received a letter from The NASDAQ Stock Market indicating that the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days.
OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.
Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.
Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust have introduced an alternative method to diagnose the cause of death, which in many cases can replace the need for the traditional invasive autopsy. This can be purchased by the family and will be performed within the NHS hospitals.
Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.
› Verified 1 days ago
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356783351 PECOS PAC ID: 8022927342 Enrollment ID: O20031215000462 |
News Archive
Commonwealth Biotechnologies, Inc. ("CBI" or "Company")) (NASDAQ Capital Market:CBTE) today announced that on September 15, 2009, CBI received a letter from The NASDAQ Stock Market indicating that the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days.
OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.
Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.
Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust have introduced an alternative method to diagnose the cause of death, which in many cases can replace the need for the traditional invasive autopsy. This can be purchased by the family and will be performed within the NHS hospitals.
Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.
› Verified 1 days ago
| Entity Name | Portercare Adventist Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760761928 PECOS PAC ID: 0941110886 Enrollment ID: O20090115000327 |
News Archive
Commonwealth Biotechnologies, Inc. ("CBI" or "Company")) (NASDAQ Capital Market:CBTE) today announced that on September 15, 2009, CBI received a letter from The NASDAQ Stock Market indicating that the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days.
OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.
Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.
Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust have introduced an alternative method to diagnose the cause of death, which in many cases can replace the need for the traditional invasive autopsy. This can be purchased by the family and will be performed within the NHS hospitals.
Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.
› Verified 1 days ago
| Entity Name | Rocky Vista Health Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366606709 PECOS PAC ID: 1052443710 Enrollment ID: O20100715000149 |
News Archive
Commonwealth Biotechnologies, Inc. ("CBI" or "Company")) (NASDAQ Capital Market:CBTE) today announced that on September 15, 2009, CBI received a letter from The NASDAQ Stock Market indicating that the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days.
OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.
Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.
Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust have introduced an alternative method to diagnose the cause of death, which in many cases can replace the need for the traditional invasive autopsy. This can be purchased by the family and will be performed within the NHS hospitals.
Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.
› Verified 1 days ago
| Entity Name | Knd Development 59 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447747654 PECOS PAC ID: 3678602802 Enrollment ID: O20170128000179 |
News Archive
Commonwealth Biotechnologies, Inc. ("CBI" or "Company")) (NASDAQ Capital Market:CBTE) today announced that on September 15, 2009, CBI received a letter from The NASDAQ Stock Market indicating that the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days.
OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.
Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.
Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust have introduced an alternative method to diagnose the cause of death, which in many cases can replace the need for the traditional invasive autopsy. This can be purchased by the family and will be performed within the NHS hospitals.
Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edward Anthony Malcolm, DO 7700 S Broadway, Littleton, CO 80122-2602 Ph: (303) 730-8900 | Edward Anthony Malcolm, DO 7700 S Broadway, Littleton, CO 80122-2602 Ph: (303) 730-8900 |
News Archive
Commonwealth Biotechnologies, Inc. ("CBI" or "Company")) (NASDAQ Capital Market:CBTE) today announced that on September 15, 2009, CBI received a letter from The NASDAQ Stock Market indicating that the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days.
OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.
Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.
Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust have introduced an alternative method to diagnose the cause of death, which in many cases can replace the need for the traditional invasive autopsy. This can be purchased by the family and will be performed within the NHS hospitals.
Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.
› Verified 1 days ago
Dr. Erin Elizabeth Riggle, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 15 W Dry Creek Cir, Littleton, CO 80120 Phone: 303-952-1100 Fax: 303-952-8185 | |
Kathryn J Wood, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5257 S Wadsworth Blvd, Littleton, CO 80123 Phone: 303-743-5855 | |
William T Gipson, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1420 W Canal Ct, Ste 100, Littleton, CO 80120 Phone: 303-791-7540 Fax: 303-791-2241 | |
James Young Rhee, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 Southpark Dr, Littleton, CO 80120 Phone: 303-722-8987 Fax: 303-722-2935 | |
Sheanna L Barclay, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 7600 Shaffer Pkwy, Littleton, CO 80127 Phone: 303-338-4545 | |
Mary S Todd, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5257 S Wadsworth Blvd, Littleton, CO 80123 Phone: 303-743-5855 | |
Lea A Craig, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5555 E Arapahoe Rd, Littleton, CO 80122 Phone: 303-850-5868 |